Clinical Trial Update: Repeat Dose Safety Study for Compound to Treat Anemia [Phase 1]

View source ↗

Summary

GlaxoSmithKline completed a Phase 1 repeat-dose safety study of a compound intended to treat anemia in patients with kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Disease

Drugs mentioned

• Compound to Treat Anemia

Snippet

Sponsor: GlaxoSmithKline | Conditions: Kidney Disease | Phase 1 | Status: COMPLETED